Worcester's ECI Biotech Receives NIH Grant
ECI Biotech (ECI) of Worcester has received a grant to perform clinical testing on its diagnostic test for joint infections following surgeries like hip or knee replacements.
The $298,291 was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institute of Health (NIH).
CEO Mitch Sanders said, "Infection can be a very serious complication for people with knee and hip replacements. With an accurate diagnostic, clinicians will be able to determine whether the knee or hip requires a revision. Without a sensitive and rapid diagnostic for infection, patients will continue to be put through painful, time-consuming and possibly unnecessary revision surgeries."
According to ECI, knee and hip replacements have about a 15 percent chance of needing surgical revision. The study conducted with the grant money will test the accuracy of ECI's rapid diagnostic for periprosthetic joint infection, with the ultimate goal of detecting infection early to reduce the complications of an infection and the number of additional surgeries.
ECI also said it received institutional review board approval from a research hospital in the Midwest, although it has yet to announce which one.
WBJ Web Partners
Most Recent
Most Recent
0 Comments